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Abstract
Background: Treatment with beta-blockers is currently recommended after myocardial infarction (MI). The evidence
relies on trials conducted decades ago before implementation of revascularization and contemporary medical therapy
or in trials enrolling patients with heart failure or reduced left ventricular ejection fraction (LVEF ≤ 40%). Accordingly,
the impact of beta-blockers on mortality and morbidity following acute MI in patients without reduced LVEF or heart
failure is unclear.
Methods/design: The Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection
fraction (DANBLOCK) is a prospective, randomized, controlled, open-label, non-blinded endpoint clinical trial designed
to evaluate the efficacy of beta-blocker treatment in post-MI patients in the absence of reduced LVEF or heart failure.
We will randomize 3570 patients will be randomized within 14 days of index MI to beta-blocker or control for a
minimum of 2 years. The primary endpoint is a composite of all-cause mortality, recurrent MI, acute decompensated
heart failure, unstable angina pectoris, or stroke. The primary composite endpoint will be assessed through locally
reported and adjudicated endpoints supplemented by linkage to the Danish national registers. A number of secondary
endpoints will be investigated including patient reported outcomes and cardiovascular mortality. Data from similar
ongoing trials in Norway and Sweden will be pooled to perform an individual patient data meta-analysis.
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Discussion: DANBLOCK is a randomized clinical trial investigating the effect of long-term beta-blocker therapy after
myocardial infarction in patients without heart failure and reduced LVEF. Results from the trial will add important
scientific evidence to inform future clinical guidelines.
Trial registration: Clinicaltrials.gov, NCT03778554. Registered on 19 December 2018.
European Clinical Trials Database, 2018-002699-42, registered on 28 September 2018.
Keywords: Myocardial infarction, Beta-blocker treatment, Long-term prognosis, Randomized controlled trial
Background
Beta-blockers have been an essential part of secondary
prevention after myocardial infarction (MI) since land-
mark studies in the 1980s demonstrated a significantly
lower mortality associated with beta-blocker treatment
[1–3]. The benefits have been attributed to the negative
chronotropic and ionotropic features, reducing oxygen
demand, and improving coronary diastolic perfusion.
Moreover, beta-blockers reduce the sympathetic activation
and myocardial sensitivity to fatal arrhythmias [4, 5]. Dur-
ing the last decades reperfusion strategies and improved
medical therapy for secondary prevention have substan-
tially improved the prognosis for patients with MI [6].
Introduction of primary percutaneous coronary interven-
tion (PCI) has resulted in increased salvage of myocar-
dium, a smaller ischemic substrate, and a myocardium
that is less susceptible to arrhythmias [7]. Hence, long-
term oral beta-blocker therapy in patients without re-
duced left ventricular ejection fraction (LVEF) and heart
failure (HF) after MI has been questioned [8, 9].
Randomized controlled trials evaluating beta-blocker
therapy
The beta-blocker trials conducted in the 1980s and
1990s were summarized in a meta-analysis of 82 ran-
domized controlled trials documenting a significantly re-
duced mortality with beta-blocker therapy after MI [10].
However, the trials included in the meta-analysis were
performed before revascularization was standard of care.
In a recent meta-analysis comparing randomized con-
trolled trials from the pre-reperfusion and reperfusion
era, the mortality benefit was only seen in the pre-
reperfusion era [11]. The incidence ratio for mortality in
patients with and without beta-blocker treatment after
MI in the 12 studies conducted in the reperfusion era
was 0.98 (95% confidence interval (CI) 0.92–1.05). In
most trials, beta-blockers were given without systematic-
ally assessing LVEF, and although the incidence rates of
MI and angina pectoris were reduced, there was an
increased risk of HF, cardiogenic shock, and drug dis-
continuation. Analyses were not stratified by LVEF and
no trials in the reperfusion era had a follow-up period of
more than 1 year. Consequently, it is not possible to
extrapolate the results from the meta-analysis to
contemporary long-term secondary prevention in pa-
tients without HF.
In the reperfusion era only one randomized controlled
trial (CAPITAL-RCT) [12] has investigated the long-
term efficacy of beta-blockers in patients with LVEF ≥
40% after MI and successful PCI. The trial included pa-
tients with ST-elevation MI (STEMI) and suggested no
benefit of carvedilol on a composite outcome (all-cause
mortality, MI, hospitalization for HF and acute coronary
syndrome) after a median follow up time of 3.9 years.
However, the trial was not powered to detect a differ-
ence in the treatment effect for the primary endpoint as
only 801 patients were randomized.
Evidence from meta-analyses of observational studies
Given the lack of contemporary randomized controlled
trials from the reperfusion era addressing long-term
beta-blocker therapy in MI patients without HF, a num-
ber of observational and registry studies have addressed
the issue and have been summarized in meta-analyses
[11, 13–16]. A meta-analysis of seven observational stud-
ies from 1996 to 2005 evaluated the benefit of long-term
beta-blocker therapy (> 6 months) in STEMI patients
with LVEF > 40% who underwent primary PCI [15]. The
meta-analysis found long-term beta-blocker therapy to
be associated with decreased all-cause mortality (com-
bined hazard ratio 0.79, 95% CI 0.65–0.97). A total of
10,857 patients were included in the analysis and follow-
up duration ranged from 6months to 5.2 years. Another
meta-analysis included ten observational studies of pa-
tients treated with PCI for either non-ST-elevation MI
(NSTEMI) or STEMI with a follow up of at least 3
months. No significant mortality benefit was found in
the subgroup of patients with preserved LVEF (relative
risk 0.79, 95% CI 0.59–1.07) [16]. Follow-up duration
ranged between 6months and 4 years and a potential ef-
ficacy of beta-blocker therapy appeared to gradually dis-
appear > 1 year after MI. A third meta-analysis including
a systematic review based on 16 observational studies
from 2010 to 2017 found a reduction in all-cause mor-
tality among almost 200,000 post-MI patients without
HF (rate ratio 0.74, 95% CI 0.64–0.85). However, publi-
cation bias and a small study effect were present. The
beneficial effect of beta-blocker therapy disappeared
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when controlling for bias, suggesting no improved
survival with beta-blocker therapy (rate ratio 0.90, 95%
CI 0.77–1.04) [13].
Observational studies have thus yielded disparate re-
sults and one concern is that they are likely to suffer
from confounding by indication as beta-blockers are
often avoided in, for example, elderly patients, who have
a high burden of comorbidity. In a UK registry-based
study including 179,810 MI patients with LVEF > 30%,
beta-blockers were prescribed in 95% of the patients.
Significant differences in baseline characteristics among
the beta-blocker and non-beta-blocker group were evi-
dent [17], suggesting that use of beta-blocker therapy is
so wide-spread that observational studies are not likely
to clarify the value of beta-blocker therapy, even when
applying advanced models to adjust for bias. Indeed, this
registry-based study found lower mortality rate among
patients treated with beta-blockers, but after propensity
score and instrumental variable analysis, no difference in
survival was found among the two groups.
Guideline recommendations
Given these uncertainties, contemporary guidelines dif-
fer regarding recommendations of beta-blocker therapy.
The American College of Cardiology/American Heart
Association (ACC/AHA) recommend beta-blocker ther-
apy with a class I recommendation (level of evidence
(LOE) B) in patients with STEMI [8], but acknowledge
that long-term beta-blocker therapy has not been pro-
spectively addressed. The European Society of Cardi-
ology (ESC) Guidelines for the management of acute MI
in patients presenting with STEMI recommend that oral
beta-blocker therapy should be considered during hos-
pital stay and continued thereafter in all patients without
contraindications with a class IIa recommendation (LOE
B) [18]. For NSTEMI patients with preserved LVEF the
ACC/AHA guidelines find it reasonable to continue
beta-blocker therapy with a class IIa recommendation
(LOE C) [19], whereas the ECS 2015 guideline has no
recommendations concerning non-ST-elevation acute
coronary syndromes [20]. In contrast, the 2013 NICE
guideline recommends continuing beta-blocker therapy
for at least 1 year after MI in patients without reduced
LVEF or HF [21].
Compliance and side effects
Beta-blockers are generally well tolerated, but side-
effects are common and may adversely affect quality of
life [1, 2]. Compared with other cardiovascular medica-
tions, a lower compliance with beta-blocker treatment is
found, suggesting a relation to side effects [22, 23]. How-
ever, not all of these side effects are supported by evi-
dence from randomized trials [24].
Objectives
Given the lack of clear evidence, there has been a call
for randomized trials [8, 9, 25, 26]. The objective of the
Danish trial of beta-blocker treatment after myocardial
infarction without reduced ejection fraction (DAN-
BLOCK) is to evaluate the continued efficacy of long-
term beta-blocker therapy after MI in patients without
HF. The study hypothesizes that beta-blocker therapy is
superior to standard of care without beta-blockers fol-
lowing MI in patients without reduced LVEF (> 40%)
and HF receiving contemporary treatment.
Methods/design
Trial design
DANBLOCK is a Danish multicenter, prospective, ran-
domized, controlled, open-label, non-blinded endpoint
clinical trial designed to evaluate the benefits of long-
term oral beta-blocker therapy in patients discharged
after an acute MI without HF. The aim is to randomize
3570 patients 1:1 to beta-blocker therapy or no beta-
blocker therapy. A study overview is presented in Fig. 1.
The expected enrolment period is 2 years and the antici-
pated duration of the trial is approximately 4 years with
subsequent publication of trial results. The trial is de-
signed to achieve a pre-specified number of events.
Study patients will be followed for all clinical endpoints
until the end of the trial.
Eligibility criteria
Study patients must be at least 18 years old, have
suffered a first-time or recurrent MI within the previous
14 days, and have an LVEF > 40% estimated by an echo-
cardiographic examination after MI. MI is defined using
the criteria developed by the Third Universal Definition
of Myocardial Infarction [27]. Indications and contrain-
dications to beta-blocker therapy are all relative and
assessed by the attending physician and study nurse.
Any indication or contraindication will exclude the pa-
tient from the trial. Patients treated with a beta-blocker
prior to the MI or initiated during the current hospital
admission are also eligible (e.g., if the indication is based
on a prior MI). Eligible patients may be randomized
prior to, after, or without a coronary angiography. Pa-
tients will be randomized after informed consent has
been obtained by the study personal. A full list of inclu-
sion and exclusion criteria is given in Table 1.
Medical treatment and adherence
After informed consent has been collected, study pa-
tients will be randomized 1:1 to receive either beta-
blocker therapy or standard treatment without beta-
blockers. After randomization both treatment groups
will receive standard care after MI and no trial-specific
visits are planned. Type and dosage of beta-blocker are
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at the discretion of the treating physician. The following
generic beta-blockers and dosages are recommended:
metoprolol succinate up to a total dosage of 200 mg
daily, bisoprolol up to a total dosage of 10 mg daily, car-
vedilol up to a total dosage of 50 mg daily, and nebivolol
up to a total dosage of 10 mg daily. It is recommended
to titrate to the highest dosage tolerated. The patient will
cover cost of medicine.
The patient’s general practitioner will be informed of
the trial in the discharge letter and will be encouraged to
maintain the patient in the group to which he or she
was randomized. Randomized patients will receive a
pocket card containing a brief explanation of the trial,
information on the randomization group, and contact
information on the local responsible investigator. Infor-
mation on compliance, dosage, and cross-over will be
monitored through e-questionnaires to the patients
every 3 months. In addition, concomitant medication at
the time of randomization and throughout the study
period will be ascertained through linkage to the Danish
Prescription Registry at study end.
Data collection and study endpoints
Primary endpoints and their rationale
The primary endpoint is a composite of all-cause mortal-
ity, recurrent MI, acute decompensated HF, unstable an-
gina pectoris, or stroke. The primary composite endpoint
was chosen for several reasons: a composite endpoint ad-
dresses a multiplicity of concerns and an integrated effect
of beta-blocker therapy is most relevant when considered
for later recommendations. All components in the com-
posite endpoint are affected by the use of beta-blockers
based on evidence from previous trials. The landmark tri-
als found a mortality benefit from betablocker treatment
[1–3] and a relative reduction of reinfarction [2, 3] and
no association was seen between beta-blocker treat-
ment and risk of incident HF [28]. In contrast, an in-
creased risk of HF with beta-blocker treatment is
Fig. 1 Study overview
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supported by a meta-analysis of 12 randomized con-
trolled trials from the reperfusion era [11]. Stroke has
been included as a component of the composite end-
point as poorer blood pressure control can potentially
occur in the non-beta-blocker group, increasing the risk
of stroke. Further, use of a single primary outcome
would have resulted in an unfeasible sample size. The
primary composite endpoint will be assessed through
locally reported and adjudicated endpoints. Adjudica-
tion will be performed through review of hospital re-
cords, applying endpoint definitions following the
objective criteria in the 2017 Cardiovascular and Stroke
Endpoint Definition for Clinical Trials [29]. At study
end data will be supplemented by linkage to the Danish
administrative and clinical registers. The use of regis-
ters will ensure no outcome data are missed.
Secondary endpoints and their rationale
The secondary endpoints are listed in Table 2 and a
schedule of enrolment, interventions, and assessments is
presented in Table 3. Among these is the effect of long-
term beta-blocker therapy on quality of life as studies in-
vestigating the side effects of beta-blocker treatment have
given disparate results. Previous trials have demonstrated
that beta-blocker therapy may increase fatigue, institute
sexual dysfunction, and lead to sleep disorders, gastro-
intestinal discomfort, cold hands, and feet, bronchospasm,
and depressive symptoms [2]. In a recent systemic review
of 15 placebo-controlled studies, however, no significant
increase in depressive symptoms was found with beta-
blocker treatment and only a small increased risk of fa-
tigue and sexual dysfunction were seen [30].
Despite complete revascularization, a significant pro-
portion of patients continues to have angina, which af-
fects quality of life and is associated with anxiety and
depression [31, 32]. Beta-blockers are first-line treatment
of angina pectoris [33], but whether routine treatment
will improve symptoms and quality of life in a contem-
porary post-MI population is unknown.
Patient reported outcomes will be collected at baseline
prior to randomization and after 3, 12, and 24months
through questionnaires (electronic or paper). The
Table 1 Inclusion and exclusion criteria
Inclusion criteria
• Myocardial infarction within 14 days according to the Universal ESC
definition of MI: Detection of a rise and/or fall of cardiac biomarker
values with at least one value above the 99th percentile upper
reference limit and with at least one of the following:
• Symptoms of ischemia
• New or presumed new significant ST-segment–T wave changes
or new left bundle branch block
• Development of pathological Q waves in the ECG
• Imaging evidence of new loss of viable myocardium or new
regional wall motion abnormality
• Age > 18 years
• LVEF > 40% by any imaging technique during hospitalization
Exclusion criteria
• Any condition that requires beta-blocker treatment according to the
treating physician, including but not limited to:
• Beta-blocker-treated arrhythmias
• Beta-blocker-treated hypertension
• Reduced left ventricular ejection fraction
• Cardiomyopathies
• Any condition in which beta-blocker treatment is contraindicated ac-
cording to the treating physician, including but not limited to:
• Hypotension
• Brady-arrhythmias
• Severe peripheral artery disease
• History of not able to tolerate beta-blocker therapy
• Severe chronic obstructive pulmonary disease or asthma
• Severe valvular heart disease
• Any condition (i.e., dementia) that could lead to increased risk for
the patient when treated with beta-blockers
• Clinical evidence of heart failure at the time of randomization
• Lack of signed informed consent and expected cooperation during
follow-up
• Pregnancy or of child bearing age not using safe contraception
throughout the study period
Table 2 Primary and secondary endpoints
Primary endpoints
• A composite of all-cause mortality and hospitalization for recurrent
non-fatal myocardial infarction, unstable angina pectoris, stroke, or
acute decompensated heart failure
Secondary endpoints
• Each of the components of the primary outcome
• Cardiovascular mortality
• Atrial fibrillation and atrial flutter
• Cardiac arrest
• Ventricular arrhythmias
• Stable angina pectoris
• Bradycardia, syncope, or need for pacemaker
• Hospitalization for asthma and chronic obstructive pulmonary disorder
• Hospitalization for diabetes (new onset and dysregulation)
• Hospitalization for dysregulated blood pressure
• Peripheral artery disease
• Blood pressure controla
• Exercise capacitya
Patient reported outcomes (PRO) regarding:
• Health-related quality of life, depression, sexual dysfunction, angina
burden following MI, and sleep disorders
aAvailable for patients attending cardiac rehabilitation
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following patient reported outcomes will be assessed:
quality of life (EuroQol-5 Domain (EQ5D) [34]), anxiety
and depression (Hospital Anxiety and Depression Scale
(HADS) [35]), sexual dysfunction (short versions of Inter-
national Index of Erectile Function (IIEF) [36] and Female
Sexual Function Index (FSFI) [37]), sleep disorders (Ber-
gen insomnia scale [38]), and symptom-burden after MI
(New York Heart Association classification (NYHA), Can-
adian Cardiovascular Society grading of angina pectoris
(CCS), Seattle Angina Questionnaire (SAQ) [39]).
Beta-blocker therapy is no longer first line treatment
for hypertension; however, routine use after MI may give
better blood pressure control than individual uptitration
and may be a part of a beneficial effect of beta-blockers.
Hence, blood pressure control has been chosen as a sec-
ondary endpoint. The use of beta-blockers in patients
with diabetes may reduce insulin sensitivity [40], in-
crease plasma glucose, mask hypoglycaemic symptoms,
or increase the risk of new onset diabetes [41–43], but
limited data are available. Furthermore, beta-blockers
are suspected to limit VO2-peak, an objective indicator
of physical capacity and a predictor of prognosis. DAN-
BLOCK will ascertain data from the Danish Cardiac
Rehabilitation Database (DHRD), a nationwide rehabili-
tation database of adults treated for ischemic cardiac dis-
ease in a Danish hospital. The database contains several
quality indicators, including, but not limited to, LVEF,
VO2−peak, incidence and control of diabetes, blood pres-
sure control, cholesterol levels, and adherence to and
dosage of beta-blockers, statins, and platelet inhibitors.
Study organization, safety, and monitoring
DANBLOCK is a nationwide Danish trial endorsed by the
Danish Society of Cardiology. The trial is investigator-
initiated and currently 26 of the 29 departments of cardi-
ology in Denmark are participating. A steering committee
is responsible for conducting the trial and reporting of the
trial results.
Every 3 months patient health records will be reviewed for
clinical endpoints and hospitalization with possible causal re-
lation to the treatment or non-treatment with beta-blockers.
Three months after the first patient is randomized and
every 6 months thereafter a Data Safety Monitoring
Board (DSMB) consisting of two senior cardiologists and
one experienced trial statistician will overview safety. In
case of an imbalance in event rates between the treat-
ment arms or if the DSMB is of the conviction that the
risk to current and future trial patients outweighs the
potential impact of continuing the trial, the DSMB will
recommend the steering committee to discontinue the
trial. DSMB members are independent and not other-
wise involved in the trial.
The trial may be discontinued for futility if the inclusion
rate is lower than expected and the trial cannot reach the
needed number of patients within a reasonable time frame
and in case of excessive cross-over. The steering commit-
tee will make any decisions of discontinuation.
Patient and public involvement
Patient groups are involved as research partners to en-
sure that the trial focuses on issues relevant to the pa-
tients and the public. Prior to enrolment of the first
patient a patient expert group has been established with
members from different backgrounds reflecting patients
eligible for the trial. The group has met to share their
experiences with beta-blocker treatment and to review
and develop patient material, questionnaires, and e-mails
to the patients included in the trial. Further meetings of
Table 3 Schedule of enrolment, interventions, and assessments
Time and assessment Enrolment Treatment period following randomization Study end
At randomization Every 3 months 3 months 1 year 2 year
Eligibility screen, informed consent, allocation to treatment group,
and collection of baseline dataa
x
Self-reported questionnaires on quality of life and symptom burdenb x x x x
Risk factor control and benefit from cardiac rehabilitationc x
Adherence to treatment groupd x x
Information on hospital admissionse x x
Endpoints from registry data x
a Data collected during hospital admission or at subsequent visit
b The following e-questionnaires on patient-reported outcomes will be administered: EQ5D, HADS, IIEF/FSFI (short versions), Bergen Insomnia Scale, NYHA, CCS,
and SAQ (for those reporting symptoms of angina)
c Data on blood pressure, serum lipids, diabetes, HbA1c, and VO2peak before and after rehabilitation through registry linkage to the Danish Heart Rehabilitation
Database. The data are available for patients participating in cardiac rehabilitation
d Self-reported continued adherence to treatment group will be gathered every 3 months. By linkage to the National Prescription Register at study end, adherence
to treatment group as well as other medications will be assessed
e Every 3months the patient’s vital status and hospitalizations will be investigated through self-reported questionnaires or review of electronic health records. All
hospital admissions will be evaluated for a possible relationship with treatment group. At study end hospital admission or death from a primary or secondary
endpoint will be ascertained from the Danish National Patient Register
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the group will be undertaken during the study period to
achieve adequate participant enrolment and ensure con-
tinued patient involvement in the process of interpret-
ation and dissemination of results.
Ongoing beta-blocker trials
In Norway and Sweden trials with comparable inclusion
criteria and endpoints are ongoing: The Swedish Random-
ized Evaluation of Decreased Usage of betablockers after
myocardial infarction in the SWEDEHEART registry
(REDUCE-SWEDEHEART, NCT03278509) and the
Norwegian BEtablocker Treatment After acute Myo-
cardial Infarction in revascularized patients without
reduced left ventricular ejection fraction (BETAMI,
NCT03646357 [44]). Both trials are designed as su-
periority trials and aim to include 7000 and 10,000
patients, respectively. Table 4 shows the characteristics of
the three Scandinavian studies. The trials primarily differ in
terms of the primary endpoint and the LVEF cutoff value.
Furthermore, a Spanish–Italian trial, REBOOT, is on-
going. REBOOT is randomizing patients after MI with a
LVEF > 40% to either beta-blocker therapy or standard
treatment without beta-blockers (NCT 03596385). The
primary outcome of REBOOT is the 3-year incidence of a
composite of all-cause mortality, reinfarction, and HF
admission.
Statistical considerations
The trial is designed to reach a pre-specified number of
events and patients will be followed for all clinical end-
points until the end of the trial. Loss to follow-up is con-
sidered negligible due to almost complete coverage by
the national registers. We must accumulate 900 events
to be able to detect an effect with a power of 80% and a
hazard ratio of 1.2 for the non-treated group compared
with the treated with regard to the primary endpoint.
Based on data from the Danish nationwide registry from
2010 to 2015, 9100 patients in Denmark suffer a first-
time or recurrent MI annually and the monthly risk of
the primary composite endpoint is 1.62%. Some patients
will not be eligible to participate in the trial or will not
wish to participate; hence, it is estimated that 1785 pa-
tients annually will be eligible and willing to sign in-
formed consent. It is expected that a 2-year recruitment
period and subsequent follow-up of 3570 patients with
aggregated events will yield the desired 900 events. In
case of a lower event rate, the inclusion period and the
follow-up period will be prolonged and a greater number
of patients will be included. Patients will be randomized
1:1 and stratified by LVEF 41–49% and ≥ 50% via a cen-
tral computerized system. Analysis will be performed
using the intention-to-treat principle with a significance
level of 5%. In addition, a per-protocol analysis will be
Table 4 Characteristics of DANBLOCK, REDUCE-SWEDEHEART, and BETAMI
DANBLOCK REDUCE-SWEDEHEART BETAMI
Inclusion criteria
Age ≥ 18 years ≥ 18 years ≥ 18 years
MI definition The universal definition of MI The universal definition of MI
(type 1)
The universal definition of MI
(type 1)
Randomized prior to Day 14 after MI Day 7 after MI Not specified
Revascularization No criteria for revascularization Obstructive coronary artery
disease documented by
coronary angiography
PCI or thrombolysis during
hospitalization
LVEF cutoff value > 40% ≥ 50% ≥ 40%
Exclusion criteria Any medical condition where
beta-blocker therapy is indicated
or contraindicated according
to the treating physician
Any medical condition where
beta-blocker therapy is indicated
or contraindicated according to
the treating physician
Any medical condition where
beta-blocker therapy is indicated
or contraindicated according to
the treating physician
Primary endpoints A composite of all-cause mortality
and hospitalization for recurrent
non-fatal MI, unstable angina
pectoris, stroke, and acute
decompensated heart failure
Time to the composite of
death of any cause or MI
Time to the composite of all
cause mortality or non-fatal MI
Expected number of randomized
patients
3570 7000 10,000
Expected number of events 900 944 794
Expected number of events
to contribute to a pooled
meta-analysis
632 944 794
Individual study power if
true HR was 1.2
0.619 0.797 0.732
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carried out. Withdrawal of consent is not expected to be
an issue throughout the study period.
Combined analysis of the Scandinavian beta-blocker trials
An adequately powered trial is needed to resolve the
question of long-term beta-blocker therapy after MI and
allow for subgroup analysis, which is possible with a
meta-analysis based on data from the three Scandinavian
studies. Hence, BETAMI, REDUCE-SWEDEHEART,
and DANBLOCK will collaborate on a combined indi-
vidual patient data meta-analysis when follow-up has
ended and data are available. By joining the three studies
more than 20,000 patients will be eligible for subgroup
analysis, including midrange LVEF, sex, age, treatment
dosage, and type of MI. Collating three nationwide trials
with pragmatic inclusion criteria, a diverse patient popu-
lation will increase generalizability of the results. To be
able to conduct the meta-analysis, DANBLOCK will re-
port the effect measure as time to the composite of
death from any cause or MI, similarly to REDUCE-
SWEDEHEART and BETAMI. Differences in inclusion
and exclusion criteria are present (Table 4) but arguably
less than typically seen in comparable meta-analyses.
With a combined expected number of events of 2370
and using a standard random effects meta-analysis, the
meta-analysis will have an overall power of 0.993 to de-
tect a HR of 1.2 using a two-sided test at 5% significance
level. Figure 2 compares the power for different sample
sizes, expressed as expected number of events, and as-
sumed effect size if data originate from a multicenter
trial and the planned random effects meta-analysis.
When varying the total sample size, the ratios between
the studies’ sample sizes are kept fixed as in the actual
Scandinavian sample sizes. As a benchmark, Fig. 2 also
reports the power obtained if the same number of pa-
tients had been included in a single large trial.
Trial status
The first patient was enrolled December 18th 2018. Re-
cruitment is expected to be complete in the 2021 and
end of follow-up in 2022. Results will be available in
2023. The full protocol is available to the public online.
The final version is 1.7 November 26th 2018. In case of
important protocol modifications, changes will be com-
municated by e-mail and/or letter to relevant parties (in-
vestigators, participants, etc.).
Discussion
DANBLOCK will add important scientific evidence for
the efficacy of beta-blocker treatment following MI in
patients without HF. The trial is designed as a prospect-
ive, randomized, controlled, open-label, non-blinded
endpoint clinical trial. The design is pragmatic and simi-
lar to standard clinical practice, which increases the
generalizability of its conclusions to routine medical care
[45]. It is possible to randomize patients who have not
undergone coronary angiography and patients who were
treated with a beta-blocker prior to the MI. This will
allow for a greater number of patients being randomized,
reducing the total inclusion time. A limitation of the se-
lected design is the lack of a placebo group with particu-
lar relevance to affect patient-reported outcomes. To
minimize this effect patients will complete the baseline
questionnaire before randomization.
Fig. 2 Minimal detectable difference between groups (HR) and statistical power in the planned meta-analyses of the three Scandinavian trials. For
comparison the greater statistical power in a single multicenter trial with the same number of events is also depicted. The solid line indicates
analysis based on data from a single multicenter trial; the dashed line indicates meta-analysis performed with a random-effects model
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LVEF cutoff value
Beta-blocker therapy has a mortality benefit in patients
with HF [46]. Consequently, patients with clinical evi-
dence of HF or LVEF ≤ 40% are excluded from the trial.
The 2016 ESC guideline introduced the classification of
LVEF into preserved (≥ 50%), midrange (40–49%), and
reduced LVEF (< 40%) [47]. Accordingly, few data exist
on midrange LVEF. Whether or not to include patients
with midrange LVEF was considered in depth. A meta-
analysis of beta-blockers for HF with reduced, mid-
range, and preserved ejection fraction demonstrated no
evidence of benefit of beta-blockers for all-cause mortal-
ity when LVEF was > 40% in sinus rhythm [48]. The on-
going trials DANBLOCK, BETAMI, and REBOOT and
the published CAPITAL-RCT [12] all include patients
with midrange LVEF. Hopefully, these trials will resolve
whether beta-blockers are beneficial in this group of
patients.
Dosage and duration of beta-blocker therapy
The appropriate length of beta-blocker therapy after MI re-
mains unclear because this issue has not been addressed in
any randomized controlled trial. In a systematic review of
propensity score matched observational studies and regres-
sion cohort studies of long term beta-blocker treatment (>
1 year, median: 3 years) in post-MI patients without HF, the
majority of studies failed to identify a benefit on mortality
or major cardiovascular events with long-term beta-blocker
therapy [49]. DANBLOCK, BETAMI, REBOOT, and
REDUCE-SWEDEHEART will investigate the long-term
efficacy with an expected treatment duration of 2–4 years.
The dosages used in contemporary clinical practice are
lower than dosages used in previous randomized clinical
trials [50] and may contribute to the lack of a mortality
benefit seen in some observational studies. Interestingly,
register-based studies suggest that an increased survival
might not be present in patients treated with dosages ap-
proximating those from the early beta-blocker trials com-
pared with a lower dosage [51]. A register-based study
showed similar rates of major adverse cardiac events
among patients receiving low-dose and high-dose beta-
blocker therapy (respectively ≤ 25% and ≥ 50% of an
equivalent daily dose of 200mg metoprolol) during 6–24
months after acute coronary syndrome (hazard ratio 1.03,
95% CI 0.70–1.50) [52]. In DANBLOCK the type and dos-
age of beta-blocker are at the treating cardiologist’s choice.
It is recommended to achieve the highest dosage tolerated.
In the discharge letter it is recommended to increase the
dosage at cardiac rehabilitation and subsequent follow-up.
Utility of withdrawal studies
Since the 1980s the proportion of adults over 65 years
who are prescribed five or more medications has tripled
[53]. The effectiveness of secondary prevention depends
on patient adherence and patients may only adhere to
half of the treatment prescribed [54]. In studies investi-
gating adherence to secondary preventive therapies after
MI, only half of the population were adherent to ACE
inhibitors/ARBs, beta-blockers, and statins [23]. In the
same study, mortality was equal between a group adher-
ent to all three medications and a group only adherent
to ACE inhibitors/ARBs and statins. Baseline character-
istic were equal in the two groups. These findings dem-
onstrate the need for withdrawal studies to ensure that
the patients are adherent to the most efficacious treat-
ment. It is in line with the ESC’s suggestion to improve
research on secondary prevention after acute coronary
syndromes to replace old evidence-based treatments in-
stead of incrementally adding new ones [55].
Conclusion
DANBLOCK will add important scientific evidence for
the efficacy of beta-blocker treatment following MI in
patients without HF and reduced LVEF. The collabora-
tive effort of the three Scandinavian studies will have the
potential of changing guidelines and clinical practice to
the benefit of these MI patients.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4214-6.
Additional file 1. World Health Organization trial registration data set.
Additional file 2. Overview of meta-analyses regarding beta-blocker
therapy after myocardial infarction.
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